maelor plc interim results the specialist healthcare products company is pleased to announce its for six months ended 30 th september 2006 financial highlights turnover up 44 1 33 million h1 2005 923 000 operating loss significantly reduced 93 429 per share of 0 22p 17p cash balance maintained at 25 24 operational good progress in implementation new strategy building a critical care business o 1st active volplex promotion sales increase 43 vs decision taken develop isoplex late stage complementary product mhra approve licence supply unlicensed medicines specials leveraging non portfolio through efficient partnerships 10 optiflo market collaboration with plethora micelle nanotechnology progressing well commenting on ceo tim wright said five ago board outlined vision establishing as an ambitious force medicine while commercialising our management team has worked determinedly over
